Merakris Therapeutics

Merakris Therapeutics' mission is to improve patient outcomes globally through regenerative biotechnology. The company positions itself as a provider of first-class subcutaneous drug treatments for leg venous ulcers and is evaluating therapies for other types of chronic wounds. Merakris Therapeutics is conducting a multicenter clinical trial using Dermacyte liquid to treat lower extremity venous stasis ulcers that have not responded effectively to standard wound care treatments.